Hyperion Therapeutics, Inc. (HPTX) Message Board
-
...in two months!...better increase the dose of ravicti before the patient keels over, doc!...HAW!...
-
...two months...HPTX looks kinda sick...I guess buying buphenyl didn't excite investors much, huh?...which is understandable since buphenyl doesn't increase the 500 patients that HPTX will have for its sole customers...
Sentiment: Strong Sell
-
...my stock's dropping like a rock...
...HPTX is buttf__king me...
...oh, when will it stop?...
...HAW!!!... -
...to the NASDAQ biotechnology index...dropped two points in the two days since it was listed...
Sentiment: Sell
- Reply to
IGXT (Mcap $31 M) 4x FDA approvals within 1 Year & Profitable this Year = 10++ Bagger Potential !!!
by medicalstaree •Apr 11, 2013 10:01 AMNDA acceptance within 2 weeks =$$$$
-
Also, that was hilarious. rrtzrealmd, the silence is deafening. To everyone else: that's it for me here on the HPTX board. You've read my investment thesis, good luck to all.
-
....competition is just raking in the dough by looking at their elaborate websites...yahoo won't let me hotlink but you can google and find the "tributyrate" website where it proclaims:
"triButyrate is the trade name for (Sodium) Phenylbutyrate (or 4-phenylbutyric acid sodium salt). triButyrate was originally developed in the mid 1980's by triple crown america, inc. at the request of Johns Hopkins Hospital as a remedy for inborn errors of urea synthesis (Urea Cycle Disorder). For this indication triButyrate/(Sodium) Phenylbutyrate is today the Active Pharmaceutical Ingredient (API) of the registered drug to treat Urea Cycle Disorder in the United States of America."
...they been selling the stuff for THIRTY YEARS and that's the best website design they can offer?!...HAW!!!...
...but it gets worse -- google "triplecrownamerica" and look at the same cheesy looking website design where its other subsidiaries "eurohealth" and "totaloralhygiene" sell such advanced products as DHEA and melatonin!...HAW!!!...
....and just THINK!...that's AFTER thirty YEARS of selling "tributyrate"!!!...yeah, baby, no doubt they're just rollin' in the dough!...
...shades of HPTX's future perhaps?...HAW, HAW, HAW!!!...Sentiment: Strong Sell
-
Yup, straight from the prospectus: "prior to approving Ravicti". Last I checked the drug was approved earlier this year.
-
...ol' illiterate "fields59" proably also missed this little tidbit:
"The FDA allowed in the approved labeling only the data it felt was adequately established and not exploratory. The labeling focuses on the showing that Ravicti was non-inferior to BUPHENYL for the treatment of UCD based on measures of ammonia control.
The FDA did not accept labeling regarding a pooled analysis of data from the clinical trials on Ravicti showing Ravicti’s superior ammonia control to BUPHENYL, Ravicti’s reduction of HA crises, or Ravicti’s improvement in executive function in UCD patients aged 6 through 17 years."
...in other words, as I have pointed out previously, HPTX can ONLY say ravicti is NON-INFERIOR to buphenyl and -- consequently -- WON'T be able charge more than the cost of buphenyl...
...or at least, third party reimbursers WON'T pay more for ravicti REGARDLESS of what HPTX tries to charge...
...tack that on to the already SHRINKING profit margins imposed by MANDATED discounts for medicaid and medicare accounts -- i.e. practically ALL of HPTX's customers -- and pretty soon, there won't be a thin DIME that HPTX will be able to squeeze out of ravicti!...
...HAW, HAW, HAW!!!...Sentiment: Strong Sell
-
...HAW!!!...you DIMWIT!!...that's straight out of HPTX's PROSPECTUS!!...plueeeze tell me you read their PROSPECTUS!...HAW!!!...here, allow me to quote it just in case you don't know how to look it up:
"Our proposed labeling for Ravicti includes dose adjustment based on levels of urinary phenylacetylglutamine, or PAGN....A test for urinary PAGN may be considered a companion diagnostic test by the FDA. We have not discussed our PAGN-based dosing adjustment labeling strategy with the FDA and do not know whether the FDA will accept a Laboratory Developed Test or instead will consider the test a companion diagnostic and therefore require a Premarket Approval Application, a filing through the de novo reclassification process, or 510(k) clearance for a urinary PAGN test, prior to approving Ravicti. If FDA approval or clearance of a urinary PAGN test is required, any approval and launch of Ravicti could be delayed and additional costs would be required for us to reach agreement with a clinical laboratory or a third-party in vitro diagnostic test manufacturer to seek and obtain premarket approval, de novo reclassification, or premarket clearance from the FDA. The State of New York approval process, and the FDA premarket review process if required, can be lengthy and would require submission of clinical study data."
...HAW!!...I guess if ignorance is bliss, you must be living in seventh heaven!...TYPICAL biotech investor!!...HAW, HAW, HAW!!!!...Sentiment: Strong Sell
-
rrtzrealmd, I'm hugely disappointed. I thought you were actually doing some original thinking about this company and it turns out you're just paying for reports and then regurgitating their analyses here. A tip: if one of the analysts has told you HPTX might be forced, *post-approval*, to file a 510k application... well that person doesn't know what a 510k application is.
-
...in the first hour of trading!...HPTX better start cranking out some more MEANINGLESS press releases before that 10-Q arrives!...HAW, HAW, HAW!!!...
Sentiment: Strong Sell
-
...I mean, HPTX goes out of its way to produce two absolutely meaningless press releases in order to staunch the bleeding in its stock price and does the market even blink in gratitude?!...
...I mean up a measly half buck on 250,000 shares yesterday only to be followed today by LOSING half of that on all of 16 THOUSAND shares?...
...don't they understand how much work goes into these meaningless press releases?!!...
...what WILL it take to impress these people?!...HAW, HAW, HAW!!!!...Sentiment: Strong Sell
-
...I said yesterday you could expect a stream of meaningless press releases to start anytime now since HPTX would want to stem the bloodletting!...and voila!...this morning they kindly oblige with ONE press release announcing they're acquiring rights to buphenyl and ammonul and ANOTHER press release saying that they acquired "orphan drug exclusivity" for ravicti!...
...well, considering they anticipate having only five HUNDRED patients REGARDLESS of whether they're selling ravicti or buphenyl, you have to wonder exacly how much value there is in having "orphan drug exclusivity" -- right?...
...an then again, if ravicti is all so special why does HPTX want to acquire rights to its competitors buphenyl and ammonul?...why pay MILLIONS of dollars to acquire rights to drugs when YOUR drug is allegedly so superior?....
...and did you notice this is starting with the earnings report due within the next two weeks?...
....and the wheels on the biotech bus go round and round!...round and round!...HAW, HAW, HAW!!!...Sentiment: Strong Sell
-
...at "fields59" brilliant explanation as to why HPTX has dropped over 25% in the past month:
"down days like this are often very rough on small cap biotechs."
...ohhh, wait for it!..............just hold on!...........can't keep it in any longer:
HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW!!!!
....oh, man, that was a relief!..HAW!!...
....of course, the FACT that the company itself admits it will have only five HUNDRED patients who will be buying its product and the FACT that MOST of them depend on Medicaid to pay for their therapy and the FACT that, in consequence, HPTX will be FORCED to sell its product at a substantial DISCOUNT -- I guess that none of that had anything to do with thr drop, huh?...
...and ditto for the FACT that it was Brenda Sandburg of Elsevier Business Intelligence who pointed out that based on current numbers, revenues for HPTX will likely not exceed 30 million dollars?...
...and ditto for the FACT that Rhonda Greenapple, founder and CEO of Reimbursement Intelligence, said, "If they can show patients on their drug are more adherent and have better health outcomes, it’s worth the money. In order to be really successful they would need data behind it." -- the problem being that so far HPTX has absolutely ZERO data to support any claim of superiority which is why the FDA FORCES HPTX to include a disclaimer on the drug insert saying that ravicti is ONLY "non-inferior" to competing products?...
...and ditto for the FACT that dose adjustment of ravicti is based results of a test for levels of urinary phenylacetylglutamine which the FDA will likely FORCE HPTX to file a 510k application which will take time and money to complete?...
...NONE of those matter?...why, of course not!...at least not to SUCKERS!...HAW, HAW, HAW!!!!...Sentiment: Strong Sell
-
I am new to HPTX. Thanks again for your info. I will read your earlier posts.
-
...oh!!!...I know!...I know!!!...call on me!!...call on me!!!...
...ahem!...it's because sh_t is heavier than the empty bag of gas that stock jobbers are trying to pass off as HPTX!...
...feel free to read all of my previous posts for all the dirty sordid little details!...
...HAW, HAW, HAW!!!....Sentiment: Strong Sell
-
Bolton - down days like this are often very rough on small cap biotechs. With HPTX I think this is also part of a cooling off period after the IPO euphoria (see my post from several weeks ago about how we'd likely fall back toward $20). It's up 100% since the IPO and the lock-up period is over as far as I know, so there may be some profit taking from the institutional investors. The last piece is that a generic NaPBA was approved recently. I've posted before how Ravicti is a better drug (ignore rrtzrealmd's lunatic posts on non-inferiority and an imaginary $30 million revenue cap - he is trying to win back some major losses) but the existence of generic NaPBA does put more pressure on HPTX to move patients to their drug.
-
...I saw $20.15 cross the tape!...I guess at least someone's getting nervous!...next thing you know you'll see the beginning of the stream of meaningless press releases -- just like OMER's been doing -- to try and prop the price up...fortunately, the street -- as demonstrated by OMER's miserable failure -- has wised up to such nonsense...
...now the question is where will HPTX find support -- 20, 15, 10, 5, or maybe even lower!...
...and when you consider the customer base:
"We estimate that the number of individuals in the United States with UCD is approximately 2,100, of which approximately 1,100 are currently diagnosed and approximately 425 are treated with BUPHENYL, and 90 are treated with Ravicti. Of these, we estimate that approximately 60% are children and 40% are adults."
...wow!...just think!...your company depends upon all of five HUNDRED customers -- most of whom depend on MEDICAID to pay for their therapy!...now that oughta produce soom BOOMIN' sales figures!...
....more ESPECIALLY after HPTX announces that the FDA will require a separate 510k approval for the urinary phenylacetylglutamine test that is REQUIRED to monitor appropriate dosages of the drug...and since HPTX doesn't do the test themselves, they will have to find some lab willing to undertake the onerous task of gaining approval even thought the lab itself might never see revenues from the test...
...oh, yes, that little announcement will certainly take a lot of the wind out of HPTX's sails, I should think!...
...don't you agree?...HAW, HAW, HAW!!!!....Sentiment: Strong Sell
-
Thank you. Do you know why HPTX falls like a rock?
Chromebooks land at more retail stores
CBSTV Videos - 27 minutes agoEntertainment News Pop: Crystal, Goodman Head Back to School in 'Monsters University'
Wochit - 1 hour 27 minutes agoThis Stock Has A Secret Asia Problem
Talking Numbers - 2 hours 6 minutes ago